Because clinical data are limited, current American Society of Hematology guidelines have conditional recommendations with low levels of certainty for the use of ACEi/ARB to treat sickle cell nephropathy.[2] In a longitudinal cohort of SCD patients, we demonstrate that there may be a benefit of ACEi/ARBs in reducing albuminuria independent of APOL1 risk status. This evidence concerns the gene APOL1 and Schnyder corneal dystrophy.